ClinicalTrials.gg
CompletedNCT00237185Updated Aug 19, 2014Results posted

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

A Phase 2 interventional study of Imatinib mesylate in Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST), sponsored by Novartis Pharmaceuticals. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing imatinib in Gastrointestinal Stromal Tumors — 8 open to participants now, 9 under way, 2 of them phase 3. imatinib · Gastrointestinal Stromal Tumors.

Enrollment
8th of 50
148 · median 56
Started
2000
with 2 others
Phase 2
25 of 50
5 open now
Registered
13th of 50
by date
Lead sponsor
10 of 50
Novartis Pharmaceuticals

Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, this one is the 8th largest by enrollment, is one of 3 that started in 2000, is one of 25 in phase 2, and was the 13th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

8 of the 50 studies testing imatinib in Gastrointestinal Stromal Tumors are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing imatinib in Gastrointestinal Stromal Tumors, or all of them as a file.
02

Study summary

In the core study, participants with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit were treated with either 400 mg or 600 mg imatinib mesylate for 3 years. The 10 year extension study allowed participants, who successfully completed the core study, to continue study treatment with imatinib mesylate provided they still benefited from treatment and did not demonstrate safety concerns as per the investigator's opinion.

03

Conditions studied

  • Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)

Keywords

  • GIST
  • c-kit
  • imatinib mesylate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and non-pregnant women ≥18 years of age with the histopathologically documented diagnosis of malignant GIST that was unresectable and/or . Confirmation of KIT (CD117) expression via immunohistochemical analysis of tumor sample was also required
  • At least one , as defined by Southwestern Oncology Group (SWOG) Solid Tumor Response Criteria, which had not been previously embolized or irradiated
  • Performance status ≤3 as defined by the (ECOG) criteria, as well as a ≥6 months and adequate end organ function defined as follows: Total \<1.5 times (ULN), (SGOT) and alanine aminotransferase (SGPT) \<2.5 x ULN (or \<5 x ULN if hepatic metastases were present), creatinine \<1.5 x ULN, (ANC) >1.5 x 10\^9/L, count >100 x 10\^9/L

Exclusion criteria

Exclusion Criteria:

  • Patients with fewer than five years of disease-free survival from any other (non-GIST) except if the other malignancy was not currently and did not require active intervention or if the other malignancy was a basal cell skin cancer or a cervical carcinoma in situ
  • Patients with known
  • Evidence of any of the following disorders: Grade III/IV cardiac failure as defined by the Criteria, severe concomitant disease, acute or known chronic liver disease (i.e. chronic active hepatitis, cirrhosis) or infection
  • Chemotherapy or other therapy within four weeks prior to study entry (six weeks for nitrosourea or mitomycin-C) and/or radiotherapy to ≥25% of the bone marrow
  • Inability to cooperate
  • Major surgery within two weeks or exposure to other investigational agents within 28 days of entry into the study

Other protocol-defined inclusion / exclusion criteria may have applied.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    imatinib mesylate 400 mg

    400 mg once daily

    Drug: Imatinib mesylate

  • Experimental
    imatinib mesylate 600 mg

    600 mg once daily

    Drug: Imatinib mesylate

Interventions

  • Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.

    Also known as: Glivec, Gleevec

06

What researchers measure

Primary outcomes

  1. Best Tumor Response (Core)

    Best tumor response was based on the Southwestern Oncology Group (SWOG) criteria. Objective tumor response assessments were categorized according to the following criteria: complete response (CR), partial response (PR), no change or stable disease (SD), progression of disease (PD), unknown where the progression has not been documented and one or more measurable or evaluable sites have not been assessed (UNK), status after resection for progression (RP), status after resection for safety (RS), status after preventive resection (RPR), progressive after first resection (PDR) and not evaluable. Any tumor assessment after surgical resection for preventative reasons was treated like tumor assessments of UNK for calculation of best response. Tumor assessments with current objective status = RP, RS or PDR were treated like assessments with objective tumor status = PD n the calculation of best response.

    Time frame: Month 36

  2. Best Tumor Response (Core + Extension)

    Best tumor response was based on the Southwestern Oncology Group (SWOG) criteria. Objective tumor response assessments were categorized according to the following criteria: complete response (CR), partial response (PR), no change or stable disease (SD), progression of disease (PD), unknown where the progression has not been documented and one or more measurable or evaluable sites have not been assessed (UNK), status after resection for progression (RP), status after resection for safety (RS), status after preventive resection (RPR), progressive after first resection (PDR) and not evaluable. Any tumor assessment after surgical resection for preventative reasons was treated like tumor assessments of UNK for calculation of best response. Tumor assessments with current objective status = RP, RS or PDR were treated like assessments with objective tumor status = PD n the calculation of best response.

    Time frame: Month 156

Secondary outcomes

  1. Overall Survival (Core)

    Overall survival was analyzed as time to event for all participants. Participants who did not die were censored at the last date known alive, which is the last date of any study medication, laboratory sample, tumor assessment, adverse event end date or date of last contact.

    Time frame: Date of first imatinib dose to the date of death during the core period, up to 36 months.

  2. Overall Survival (Core + Extension)

    Overall survival was analyzed as time to event for all participants. Participants who did not die were censored at the last date known alive, which is the last date of any study medication, laboratory sample, tumor assessment, adverse event end date or date of last contact.

    Time frame: Date of first imatinib dose to the date of death during the core and extension periods, up to 156 months.

  3. Duration of Response (Core)

    Duration of response was analyzed as time to event for all participants whose best response was at least a PR. The onset of response was the first tumor assessment that was subsequently confirmed to constitute at least a partial best response. The end of response was the first tumor assessment noting PD.

    Time frame: Date of confirmed best PR or CR to date of confirmed disease progression during the core period, up to 36 months.

  4. Duration of Response (Core + Extension)

    Duration of response was analyzed as time to event for all participants whose best response was at least a PR. The onset of response was the first tumor assessment that was subsequently confirmed to constitute at least a partial best response. The end of response was the first tumor assessment noting PD.

    Time frame: Date of confirmed best PR or CR to date of confirmed disease progression during the core and extension periods, up to 156 months

  5. Progression Free Survival (PFS) (Core + Extension)

    Progression free survival was analyzed as a time to event for each participant. If a participant had no event, then the PFS was censored at the last tumor assessment.

    Time frame: Date of first imatinib dose to earliest date of progression, resection due to safety/progression, death due to any cause or discontinuation due to unsatisfactory therapeutic effect during the core and extension periods, up to 156 months.

  6. Time to Treatment Failure (Core)

    Time to treatment failure was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis ate the time of their last tumor assessment.

    Time frame: Date of first imatinib dose to date of earliest occurrence of progression, death due to any cause, or discontinuation from the trial for any reason other than the condition no longer required therapy during the core period, up to 36 months.

  7. Time to Treatment Failure (Core + Extension)

    Time to treatment failure was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis at the time of their last tumor assessment.

    Time frame: Date of first imatinib dose to date of earliest occurrence of progression, death due to any cause, or discontinuation from the trial for any reason other than the condition no longer required therapy during the core and extension periods, up to 156 month.

  8. Time to Onset of Response (Core)

    Time to response was analyzed as time to event for all participants. Participants who did not meet the definition of confirmed PR/CR were censored at the time of their last progression-free tumor assessment.

    Time frame: Date of first imatinib dose to the date of the first tumor assessment that was later confirmed to be at least a partial response during the core period, up to 36 months.

  9. Time to Onset of Response (Core + Extension)

    Time to response was analyzed as time to event for all participants. Participants who did not meet the definition of confirmed PR/CR were censored at the time of their last progression-free tumor assessment.

    Time frame: Date of first imatinib dose to the date of the first tumor assessment that was later confirmed to be at least a partial response during the core and extension periods, up to 156 months.

  10. Time to Progression (Core + Extension)

    Time to progression was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis at the time of their last tumor assessment.

    Time frame: Date of first imatinib dose to date of progression or death due to disease indication or discontinuation due to unsatisfactory therapeutic effect during the core and extension periods, up to 156 months.

07

Results

Posted Jul 15, 2014
Limitations and caveats
No safety data was collected in the extension.

Participant flow

Core
Participant flow — Core
MilestoneImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Started7474
Treated participants7374
Completed3037
Not completed4437
Withdrew: Adverse event34
Withdrew: Abnormal laboratory value04
Withdrew: Abnormal test procedure results10
Withdrew: Lack of efficacy3023
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject44
Withdrew: Administrative problems01
Withdrew: Death40
Withdrew: Determined ineligible post randomization10
Extension
Participant flow — Extension
MilestoneImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Started2432
Completed813
Not completed1619
Withdrew: Adverse event10
Withdrew: Abnormal laboratory value01
Withdrew: Lack of efficacy914
Withdrew: Condition no longer required study drug01
Withdrew: Withdrawal by subject32
Withdrew: Lost to follow-up10
Withdrew: Administrative problems10
Withdrew: Death11

Outcome measures

PrimaryBest Tumor Response (Core)

Best tumor response was based on the Southwestern Oncology Group (SWOG) criteria. Objective tumor response assessments were categorized according to the following criteria: complete response (CR), partial response (PR), no change or stable disease (SD), progression of disease (PD), unknown where the progression has not been documented and one or more measurable or evaluable sites have not been assessed (UNK), status after resection for progression (RP), status after resection for safety (RS), status after preventive resection (RPR), progressive after first resection (PDR) and not evaluable. Any tumor assessment after surgical resection for preventative reasons was treated like tumor assessments of UNK for calculation of best response. Tumor assessments with current objective status = RP, RS or PDR were treated like assessments with objective tumor status = PD n the calculation of best response.

Time frame:
Month 36
Reported as:
Number · participants
Best Tumor Response (Core)
participantsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Complete response01
Partial response4949
Stable disease1013
Progressive disease126
Not evaluable23
Unknown02
PrimaryBest Tumor Response (Core + Extension)

Best tumor response was based on the Southwestern Oncology Group (SWOG) criteria. Objective tumor response assessments were categorized according to the following criteria: complete response (CR), partial response (PR), no change or stable disease (SD), progression of disease (PD), unknown where the progression has not been documented and one or more measurable or evaluable sites have not been assessed (UNK), status after resection for progression (RP), status after resection for safety (RS), status after preventive resection (RPR), progressive after first resection (PDR) and not evaluable. Any tumor assessment after surgical resection for preventative reasons was treated like tumor assessments of UNK for calculation of best response. Tumor assessments with current objective status = RP, RS or PDR were treated like assessments with objective tumor status = PD n the calculation of best response.

Time frame:
Month 156
Reported as:
Number · participants
Best Tumor Response (Core + Extension)
participantsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Complete response12
Partial response4948
Stable disease1013
Progressive disease116
Not evaluable23
Unknown02
SecondaryOverall Survival (Core)

Overall survival was analyzed as time to event for all participants. Participants who did not die were censored at the last date known alive, which is the last date of any study medication, laboratory sample, tumor assessment, adverse event end date or date of last contact.

Time frame:
Date of first imatinib dose to the date of death during the core period, up to 36 months.
Reported as:
Median · months
Overall Survival (Core)
monthsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Overall Survival (Core)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival (Core + Extension)

Overall survival was analyzed as time to event for all participants. Participants who did not die were censored at the last date known alive, which is the last date of any study medication, laboratory sample, tumor assessment, adverse event end date or date of last contact.

Time frame:
Date of first imatinib dose to the date of death during the core and extension periods, up to 156 months.
Reported as:
Median · months
Overall Survival (Core + Extension)
monthsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Overall Survival (Core + Extension)55.9 (34.6 to 85.9)57.1 (43.8 to 99.7)
SecondaryDuration of Response (Core)

Duration of response was analyzed as time to event for all participants whose best response was at least a PR. The onset of response was the first tumor assessment that was subsequently confirmed to constitute at least a partial best response. The end of response was the first tumor assessment noting PD.

Time frame:
Date of confirmed best PR or CR to date of confirmed disease progression during the core period, up to 36 months.
Reported as:
Median · weeks
Duration of Response (Core)
weeksImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Duration of Response (Core)113 (83 to NA)123 (79 to NA)
SecondaryDuration of Response (Core + Extension)

Duration of response was analyzed as time to event for all participants whose best response was at least a PR. The onset of response was the first tumor assessment that was subsequently confirmed to constitute at least a partial best response. The end of response was the first tumor assessment noting PD.

Time frame:
Date of confirmed best PR or CR to date of confirmed disease progression during the core and extension periods, up to 156 months
Reported as:
Median · months
Duration of Response (Core + Extension)
monthsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Duration of Response (Core + Extension)27 (22 to 46)30 (18 to 56)
SecondaryProgression Free Survival (PFS) (Core + Extension)

Progression free survival was analyzed as a time to event for each participant. If a participant had no event, then the PFS was censored at the last tumor assessment.

Time frame:
Date of first imatinib dose to earliest date of progression, resection due to safety/progression, death due to any cause or discontinuation due to unsatisfactory therapeutic effect during the core and extension periods, up to 156 months.
Reported as:
Median · months
Progression Free Survival (PFS) (Core + Extension)
monthsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Progression Free Survival (PFS) (Core + Extension)19.3 (16.4 to 28.9)25.2 (16.4 to 33.8)
SecondaryTime to Treatment Failure (Core)

Time to treatment failure was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis ate the time of their last tumor assessment.

Time frame:
Date of first imatinib dose to date of earliest occurrence of progression, death due to any cause, or discontinuation from the trial for any reason other than the condition no longer required therapy during the core period, up to 36 months.
Reported as:
Median · weeks
Time to Treatment Failure (Core)
weeksImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Time to Treatment Failure (Core)84 (71 to 107)84 (71 to 144)
SecondaryTime to Treatment Failure (Core + Extension)

Time to treatment failure was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis at the time of their last tumor assessment.

Time frame:
Date of first imatinib dose to date of earliest occurrence of progression, death due to any cause, or discontinuation from the trial for any reason other than the condition no longer required therapy during the core and extension periods, up to 156 month.
Reported as:
Median · months
Time to Treatment Failure (Core + Extension)
monthsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Time to Treatment Failure (Core + Extension)19 (16 to 25)19 (16 to 33)
SecondaryTime to Onset of Response (Core)

Time to response was analyzed as time to event for all participants. Participants who did not meet the definition of confirmed PR/CR were censored at the time of their last progression-free tumor assessment.

Time frame:
Date of first imatinib dose to the date of the first tumor assessment that was later confirmed to be at least a partial response during the core period, up to 36 months.
Reported as:
Median · weeks
Time to Onset of Response (Core)
weeksImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Time to Onset of Response (Core)13 (12 to 24)12 (12 to 22)
SecondaryTime to Onset of Response (Core + Extension)

Time to response was analyzed as time to event for all participants. Participants who did not meet the definition of confirmed PR/CR were censored at the time of their last progression-free tumor assessment.

Time frame:
Date of first imatinib dose to the date of the first tumor assessment that was later confirmed to be at least a partial response during the core and extension periods, up to 156 months.
Reported as:
Median · months
Time to Onset of Response (Core + Extension)
monthsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Time to Onset of Response (Core + Extension)3 (3 to 6)3 (3 to 3)
SecondaryTime to Progression (Core + Extension)

Time to progression was analyzed as time to event for all participants. Participants who had neither progressed, died nor discontinued from the trial for any reason other than the condition no longer required therapy were censored for analysis at the time of their last tumor assessment.

Time frame:
Date of first imatinib dose to date of progression or death due to disease indication or discontinuation due to unsatisfactory therapeutic effect during the core and extension periods, up to 156 months.
Reported as:
Median · months
Time to Progression (Core + Extension)
monthsImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Time to Progression (Core + Extension)19.8 (16.4 to 29.0)25.5 (16.5 to 41.5)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib Mesylate 400 mg—46/73 (63%)72/73 (98.6%)
Imatinib Mesylate 600 mg—40/74 (54.1%)73/74 (98.6%)
Most frequent serious events
Showing 10 of 128
Most frequent serious events
EventImatinib Mesylate 400 mgImatinib Mesylate 600 mg
Operation NOSSurgical and medical procedures7/736/74
Abdominal pain NOSGastrointestinal disorders5/733/74
Anaemia NOSBlood and lymphatic system disorders2/734/74
Gastrointestinal haemorrhage NOSGastrointestinal disorders3/732/74
Small intestinal obstruction NOSGastrointestinal disorders3/732/74
PyrexiaGeneral disorders3/732/74
DehydrationMetabolism and nutrition disorders3/731/74
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/731/74
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/731/74
NauseaGastrointestinal disorders2/733/74
Most frequent other events
Showing 10 of 71
Most frequent other events
EventImatinib Mesylate 400 mgImatinib Mesylate 600 mg
NauseaGastrointestinal disorders45/7354/74
Diarrhoea NOSGastrointestinal disorders43/7351/74
Muscle crampMusculoskeletal and connective tissue disorders34/7343/74
Periorbital oedemaSkin and subcutaneous tissue disorders39/7339/74
FatigueGeneral disorders35/7339/74
Rash NOSSkin and subcutaneous tissue disorders24/7333/74
HeadacheNervous system disorders22/7329/74
Vomiting NOSGastrointestinal disorders27/7325/74
Oedema peripheralGeneral disorders27/7324/74
Abdominal pain NOSGastrointestinal disorders26/7325/74

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Imatinib Mesylate 400 mgImatinib Mesylate 600 mgTotal
Mean56.6 ± 12.952.2 ± 11.1254.4 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib Mesylate 400 mgImatinib Mesylate 600 mgTotal
Female293564
Male443983
08

Study locations

5 sites
  • Dana Farber Cancer Institute Dept of Sarcoma Oncology
    Boston, Massachusetts 02115, United States
  • Oregon Health Sciences University Dept. of Oregon Health Sci.
    Portland, Oregon 97201, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Novartis Investigative Site
    Geelong, Victoria 3220, Australia
  • Novartis Investigative Site
    Helsinki, FIN-00029, Finland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2000, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2005
First posted
Oct 12, 2005
Start
Jun 2000
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Jul 15, 2014
Last update
Aug 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00237185
Responsible party
Sponsor
First posted
Oct 12, 2005
Start date
Jun 2000
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Jul 15, 2014
Last update
Aug 19, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
Novartis
study chair · Novartis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion